Search Within

Geoffrey R Oxnard

Formats
  1. Journal Article (14)
  2. Meeting Abstract (10)
Groups
  1. Department of Medicine (19)
  2. Solid Tumor Oncology Division (19)
  3. Thoracic Oncology (18)
  4. Department of Pathology and Laboratory Medicine (15)
  5. GSK Faculty (14)
  6. Human Oncology and Pathogenesis Program (14)

More Groups

People
  1. Mark Kris (15)
  2. Marc Ladanyi (14)
  3. Vincent Miller (14)
  4. Maria Arcila (13)
  5. Gregory Riely (9)
  6. William Pao (7)

More People

Years
  1. 2012 (5)
  2. 2011 (10)
  3. 2010 (4)
  4. 2009 (5)
Publications
  1. Clinical Cancer Research (6)
  2. Journal of Clinical Oncology (5)
  3. Journal of Thoracic Oncology (4)
  4. Journal of Molecular Diagnostics (2)
  5. Academic Medicine (1)
  6. Cancer (1)

More Publications

Publishers
  1. American Association for Cancer Research (6)
  2. American Society of Clinical Oncology (5)
  3. Elsevier Inc. (4)
  4. Elsevier Science, Inc. (2)
  5. American Association for the Advancement of Science (1)
  6. C M P Medica LLC * The Oncology Group (1)

More Publishers

Results (24)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Screening for germline EGFR T790M mutations through lung cancer genotyping
    Journal Article

    Oxnard, G. R.; Miller, V. A.; Robson, M. E.; Azzoli, C. G.; Pao, W.; Ladanyi, M.; Arcila, M. E.
    Journal of Thoracic Oncology (2012)

    Fulltext@MSK | Save
  • Resolving the controversy on EGFR/KRAS mutations in pulmonary squamous cell carcinoma via comprehensive pathologic assessment incorporating immunohistochemistry
    Meeting Abstract

    Rekhtman, N.; Paik, P. K.; Arcila, M. E.; Tafe, L. J.; Oxnard, G. R.; Moreira, A. L.; William, T. D.; Zakowski, M. F.; Mark, K. G.; Ladanyi, M.
    Modern Pathology (2012)

    Fulltext@MSK | Save
  • Resolving the controversy on EGFR/KRAS mutations in pulmonary squamous cell carcinoma via comprehensive pathologic assessment incorporating immunohistochemistry
    Meeting Abstract

    Rekhtman, N.; Paik, P. K.; Arcila, M. E.; Tafe, L. J.; Oxnard, G. R.; Moreira, A. L.; William, T. D.; Zakowski, M. F.; Mark, K. G.; Ladanyi, M.
    Laboratory Investigation (2012)

    Fulltext@MSK | Save
  • Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: Lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations
    Journal Article

    Rekhtman, N.; Paik, P. K.; Arcila, M. E.; Tafe, L. J.; Oxnard, G. R.; Moreira, A. L.; Travis, W. D.; Zakowski, M. F.; Kris, M. G.; Ladanyi, M.
    Clinical Cancer Research (2012)

    Fulltext@MSK | Save
  • Reply to E.M. Gilles
    Journal Article

    Oxnard, G. R.; Schwartz, L. H.; Riely, G. J.
    Journal of Clinical Oncology (2012)

    Fulltext@MSK | Save
  • Maintained sensitivity to EGFR tyrosine kinase inhibitors (TKIs) in EGFR-mutant lung cancers that recur after adjuvant TKI
    Meeting Abstract

    Oxnard, G. R.; Janjigian, Y. Y.; Arcila, M. E.; Kris, M. G.; Ladanyi, M.; Azzoli, C. G.; Miller, V. A.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Disease flare after tyrosine kinase inhibitor (TKI) discontinuation in patients with EGFR-mutant lung cancer and acquired resistance
    Meeting Abstract

    Chaft, J. E.; Oxnard, G. R.; Miller, V. A.; Kris, M. G.; Sima, C. S.; Riely, G. J.
    Journal of Clinical Oncology (2011)

    Fulltext@MSK | Save
  • Pulsatile high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer
    Journal Article

    Grommes, C.; Oxnard, G. R.; Kris, M. G.; Miller, V. A.; Pao, W.; Holodny, A. I.; Clarke, J. L.; Lassman, A. B.
    Neuro-Oncology (2011)

    Fulltext@MSK | Save
  • Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib
    Journal Article

    Oxnard, G. R.; Janjigian, Y. Y.; Arcila, M. E.; Sima, C. S.; Kass, S. L.; Riely, G. J.; Pao, W.; Kris, M. G.; Ladanyi, M.; Azzoli, C. G.; more...
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save
  • Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: Implications for clinical trial design
    Journal Article

    Chaft, J. E.; Oxnard, G. R.; Sima, C. S.; Kris, M. G.; Miller, V. A.; Riely, G. J.
    Clinical Cancer Research (2011)

    Fulltext@MSK | Save